0 10 Disruption disruption NN 11 13 of of IN 14 15 a a DT 16 20 GATA GATA NNP 21 26 motif motif NN 27 29 in in IN 30 33 the the DT 34 39 Duffy Duffy NNP 40 44 gene gene NN 45 53 promoter promoter NN 54 63 abolishes abolish VBZ 64 73 erythroid erythroid JJ 74 78 gene gene NN 79 89 expression expression NN 90 92 in in IN 93 107 Duffy-negative duffy-negative JJ 108 119 individuals individual NNS 119 120 . . . 122 125 The the DT 126 130 mRNA mrna NN 131 134 for for IN 135 138 the the DT 139 144 Duffy Duffy NNP 145 150 blood blood NN 151 156 group group NN 157 164 antigen antigen NN 164 165 , , , 166 169 the the DT 170 181 erythrocyte erythrocyte NN 182 190 receptor receptor NN 191 194 for for IN 195 198 the the DT 199 209 Plasmodium Plasmodium NNP 210 215 vivax vivax NN 216 223 malaria malaria NN 224 232 parasite parasite NN 232 233 , , , 234 237 has have VBZ 238 246 recently recently RB 247 251 been be VBN 252 258 cloned clone VBN 259 262 and and CC 263 268 shown show VBN 269 271 to to TO 272 278 encode encode VB 279 280 a a DT 281 287 widely widely RB 288 297 expressed express VBN 298 307 chemokine chemokine NN 308 316 receptor receptor NN 316 317 . . . 318 322 Here here RB 322 323 , , , 324 326 we we PRP 327 331 show show VBP 332 336 that that IN 337 340 the the DT 341 346 Duffy Duffy NNP 347 364 antigen/chemokine antigen/chemokine NN 365 373 receptor receptor NN 374 378 gene gene NN 379 380 ( ( ( 380 384 DARC DARC NNP 384 385 ) ) ) 386 388 is be VBZ 389 397 composed compose VBN 398 400 of of IN 401 402 a a DT 403 409 single single JJ 410 414 exon exon NN 415 418 and and CC 419 423 that that IN 424 428 most most JJS 429 443 Duffy-negative duffy-negative JJ 444 450 blacks black NNS 451 456 carry carry VBP 457 458 a a DT 459 465 silent silent JJ 466 470 FY*B fy*b NN 471 477 allele allele NN 478 482 with with IN 483 484 a a DT 485 491 single single JJ 492 493 T t NN 494 496 to to TO 497 498 C C NNP 499 511 substitution substitution NN 512 514 at at IN 515 525 nucleotide nucleotide NN 526 529 -46 -46 CD 529 530 . . . 531 535 This this DT 536 544 mutation mutation NN 545 552 impairs impair VBZ 553 556 the the DT 557 565 promoter promoter NN 566 574 activity activity NN 575 577 in in IN 578 587 erythroid erythroid JJ 588 593 cells cell NNS 594 596 by by IN 597 607 disrupting disrupt VBG 608 609 a a DT 610 617 binding bind VBG 618 622 site site NN 623 626 for for IN 627 630 the the DT 631 636 GATA1 gata1 NN 637 646 erythroid erythroid JJ 647 660 transcription transcription NN 661 667 factor factor NN 667 668 . . . 669 673 With with IN 674 677 the the DT 678 684 recent recent JJ 685 701 characterization characterization NN 702 704 of of IN 705 708 the the DT 709 713 FY*A FY*A NNP 714 717 and and CC 718 722 FY*B FY*B NNP 723 730 alleles allele NNS 730 731 , , , 732 737 these these DT 738 746 findings finding NNS 747 754 provide provide VBP 755 758 the the DT 759 768 molecular molecular JJ 769 774 basis basis NN 775 777 of of IN 778 781 the the DT 782 787 Duffy Duffy NNP 788 793 blood blood NN 794 799 group group NN 800 806 system system NN 807 810 and and CC 811 813 an an DT 814 825 explanation explanation NN 826 829 for for IN 830 833 the the DT 834 852 erythroid-specific erythroid-specific JJ 853 863 repression repression NN 864 866 of of IN 867 870 the the DT 871 875 DARC DARC NNP 876 880 gene gene NN 881 883 in in IN 884 898 Duffy-negative duffy-negative JJ 899 910 individuals individual NNS 910 911 . . .